This likely reflects the long-term loss of NaV1.7 and may suggest that acute pharmacological inhibition of NaV1.7 in humans may not fully replicate the CIP phenotype. The gene discussed is SCN9A; the disease is hereditary sensory and autonomic neuropathy.